Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

- PMLiVE

Mirna hires former Pfizer director as CMO

Dr Sinil Kim has extensive experience in oncology

- PMLiVE

Regulatory struggles force Aveo to cut 140 jobs

Expects FDA rejection for tivozanib in kidney cancer

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

Roche is drawn to science for YouTube campaign

Therapeutic antibodies, stem cells and Zebrafish tackled in series of fun videos

- PMLiVE

Alexza’s Peter Schineller joins Agendia

Appointed first chief commercial officer

- PMLiVE

ASCO: Amgen says viral therapy for melanoma “encouraging”

T-VEC is potential advancement in skin cancer treatment

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

Sanofi reception

Sanofi gives up on iniparib and otamixaban

Drops cancer drug and anticoagulant after negative late-stage trials

- PMLiVE

Merck KGaA to research cancer drug with Chinese biotech

German pharma firm teams up with BeiGene on BRAF inhibitor

- PMLiVE

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links